drugset / Trial / NCT01005875
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
Terminated
5 enrolled
University of Alabama at Birmingham
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is to determine the safety and efficacy of stereotactic body radiotherapy (SBRT) and treatment drug in patients with hepatocellular carcinoma.
Timeline
- Start
- 2009-11
- Primary completion
- 2012-12
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | — | — |